An arguement for no role for intra-CSF chemotherapy in the management of neoplastic meningitis

Expert Review of Neurotherapeutics

Volumn 4, Issue 4 SUPPL. 1, 2004, Pages

  Recht, Larry ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; METHOTREXATE;

BRAIN TUMOR; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CEREBROSPINAL FLUID FLOW; CLINICAL PROTOCOL; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DRUG ADMINISTRATION ROUTE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; HUMAN; LEUKEMIA; LEUKOENCEPHALOPATHY; LYMPHOMA; MENINGEAL METASTASIS; NEOPLASTIC MENINGITIS; OUTCOMES RESEARCH; PATIENT CARE; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; SOLID TUMOR; TECHNIQUE;

EID: 3242732301     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.4.S11     Document Type: Conference Paper

References (8)

1. Shapiro WR, Young, DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injection. N. Engl. J. Med. 293, 161-166 (1975).
2. Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47, 49-55 (2000).
3. 111Indium-DTPA CSF flow studies. Neurology 41, 1765-1769 (1991).
4. Glantz MJ, Hall WA, Cole BF et al. Diagnosis, management and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 75, 2919-2931 (1995).
5. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined modality therapy. Neurology 44, 1463-1469 (1994).
6. Boogerd W, Hart AAM, van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 67, 1685-1695 (1991).
7. Boogerd W, Dorresteijn LDA, van der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 55, 117-119 (2000).
8. Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for patients with non-leukemic leptomeningeal cancer: is it. chemotherapy necessary? J. Clin. Oncol. 16, 1561-1567 (1998).